By Colin KellaherThe European Medicines Agency has accepted for review an application from Regeneron Pharmaceuticals seeking approval of its linvoseltamab drug candidate for certain patients with the blood cancer multiple myeloma. Regeneron on Friday said the application covers adults with relapsed/refractory multiple myeloma who have progressed after at least three prior therapies. The Tarrytown, N.Y., biotechnology company in December filed for U.S. Food and Drug Administration approval of linvoseltamab. Write to Colin Kellaher at colin.kellaher@wsj.com(END) Dow Jones Newswires02-02-24 0641ET

Source: Wall Street Journal February 02, 2024 17:45 UTC